Global breast biopsy devices market is forecasted to generate a revenue of $1.4 billion by 2023, P&S Market Research.The growth is mainly led by product and technological innovations, increasing incidence of breast cancer cases, rising propensity for minimally invasive surgeries, and mounting number of breast cancer screening programs.
Different types of imaging modalities are used while performing breast biopsy procedure, such as mammography guided stereotactic biopsy, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), and several others. Among these, Mammography guided stereotactic biopsy has been holding the largest share in the breast biopsy devices market till now, as it is a minimally invasive procedure and the needle used does not distort the breast tissue. However, ultrasound guided biopsy is expected to be the fastest growing imaging modality during the forecast period.
During the forecast period, the breast biopsy devices industry is expected to witness the fastest growth in in Asia-Pacific (APAC), owing to growing geriatric population, increasing prevalence of breast cancer, growing awareness about breast cancer, rising healthcare expenditure, per capita income, and increasing research in breast biopsy devices in the region. According to National Institute of Cancer Prevention and Research, breast cancer is the most common cancer in women in India and accounts for about a quarter of all cancers in women in Indian cities, and the average age for breast cancer in India is almost a decade lower than that in the West.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/breast-biopsy-devices-market/report-sample
According to International Agency for Research on Cancer, in 2012, breast cancer incidences reported in India were 144,937 and the mortality rate in women in India was 70,218, which is comparatively higher than China (47,989). In order to balance these statistics, the government and several other organizations are also creating awareness about breast cancer. For instance, October has been designated as the breast cancer awareness month by the government of India, which is an annual campaign to educate people about breast cancer. Also, the Pink Initiative, a registered charity in Mumbai, creates awareness about breast cancer amongst women in India. These factors cumulatively lead to growth in the demand of breast biopsy devices in the region.
Globally, key players in the breast biopsy devices industry are launching products to gain a larger market share. For instance, in November 2017, Siemens Healthineers, a subsidiary of Siemens AG, unveiled its new Mammomat Revelation imaging system at the 2017 Radiological Society of North America (RSNA) Annual Meeting in Chicago. 3D HD Breast Biopsy uses company’s 50-degree wide-angle HD breast tomosynthesis to obtain more targeted, accurate biopsies at a lower dose. The system also offers titanium contrast-enhanced mammography exams and automated breast density measurement.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=breast-biopsy-devices-market
In August 2017, Hologic Inc. announced the commercial availability of Brevera breast biopsy system with CorLumina imaging technology, in the U.S. The Brevera system provides clinicians with more information at the point of care and results in significant cost and time savings without compromising with accuracy or patient health outcomes.
Some of the other major players operating in the breast biopsy devices market include Danaher Corporation, Argon Medical Devices Inc., Becton, Dickinson and Company, Sterylab S.R.L., Scion Medical Technologies LLC, Planmed Oy, Medtronic plc, and Cook Medical LLC.
Toll-free: +1-888-778-7886 (USA/Canada)